$APRE News

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

Aprea Therapeutics to Present at October Conferences

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On Molecular Targets And Cancer Therapeutics

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Aprea Therapeutics Expands Current Patent Portfolio

Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Aprea Therapeutics Q2 EPS $(0.07) Beats $(0.23) Estimate

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Aprea Therapeutics Announces ACESOT-1051 Enrollment Is Accelerating; Clinical Data Presentation Planned For Q4 2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors

Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) Estimate

Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5